Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
Feb 07, 2022
―
Basal Insulin, Afrezza, Rapid-Acting Insulin Analog
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Phase III
Completed
Afrezza® INHALE-1 Study in Pediatrics
Jun 22, 2021
―
Afrezza Dose 1, Afrezza Dose 2
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Phase IV
Completed
Afrezza® Dosing Optimization Study
Apr 16, 2021
―
Afrezza Inhalant Product
Type 2 Diabetes Treated With Insulin
Phase IV
Unknown
A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections
Oct 09, 2019
―
Treprostinil Inhalation Powder
Pulmonary Arterial Hypertension
Phase I
Completed
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
Mar 01, 2018
―
Afrezza Plus One Drop | Premium, One Drop | Premium
Diabetes Mellitus, Type 2
Phase IV
Unknown
A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
Oct 10, 2017
―
Afrezza
Type 1 Diabetes Mellitus
Phase II
Completed
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Aug 17, 2015
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mannkind Corp. (MNKD) have in its pipeline
MNKD is currently developing the following drugs: (Part A) Mknd-201, (Part B) Mknd-201, Clofazimine Inhalation Suspension, Insulin Degludec, Basal Insulin, Afrezza, Rapid-Acting Insulin Analog. These drug candidates are in various stages of clinical development as the company works toward FDA approval.